Opioid Use Disorder Treatment Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Description
Market Overview:
The Opioid Use Disorder (OUD) Treatment Market is expected to grow from USD 3,085 million in 2024 to USD 7,109.49 million by 2032, reflecting a compound annual growth rate (CAGR) of 11% during the forecast period.
Several factors are driving the growth of the opioid use disorder treatment market. The escalating opioid crisis, especially in regions like North America, has significantly increased the demand for effective treatment solutions. Pharmacological treatments such as methadone, buprenorphine, and naltrexone are in high demand due to their effectiveness in managing withdrawal symptoms and cravings. Furthermore, the growing recognition of opioid addiction as a medical condition has encouraged more individuals to seek treatment, further fueling market growth. Increased investments in research and development of innovative treatments, including digital therapeutics, are also contributing to the market’s expansion.
Market Drivers:
Rising Prevalence of Opioid Addiction:
The increasing global prevalence of opioid addiction is one of the main drivers of the Opioid Use Disorder (OUD) Treatment Market. The opioid crisis, particularly in North America, has resulted in a significant rise in addiction and overdose cases, prompting urgent demand for effective treatment options. For instance, the Centers for Disease Control and Prevention (CDC) has reported a notable increase in opioid-related deaths over the last decade. As more individuals seek help for opioid dependence, the demand for specialized treatment programs and medications has grown, directly influencing the market’s growth.
Market Challenges:
Stigma Surrounding Addiction:
A significant challenge in the Opioid Use Disorder (OUD) Treatment Market is the persistent stigma surrounding addiction. Despite increasing awareness of addiction as a medical condition, many individuals still face societal judgment, which discourages them from seeking treatment. This stigma leads to underreporting, delayed diagnosis, and underutilization of available treatment options. Consequently, there is a gap between the actual prevalence of opioid addiction and the number of individuals seeking help, limiting the market's growth potential.
Segmentation:
By Drug Type:
Opioid Agonists: Methadone, Buprenorphine
Opioid Antagonists: Naltrexone
Combination Therapies: Buprenorphine-Naloxone
By Age Group:
Adolescents (12-17 years)
Adults (18-64 years)
Elderly (65+ years)
By Route of Administration:
Oral
Injectable
Transdermal
By Distribution Channel:
Hospitals
Clinics
Retail Pharmacies
By Region:
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Players:
Aphios
MediciNova
Alkermes, Inc.
Titan Pharmaceuticals, Inc.
Trevena
Kyowa Kirin
Gamida-Cell
Hikma Pharmaceuticals
Opiate Pharmaceutical
Novartis AG
The Opioid Use Disorder (OUD) Treatment Market is expected to grow from USD 3,085 million in 2024 to USD 7,109.49 million by 2032, reflecting a compound annual growth rate (CAGR) of 11% during the forecast period.
Several factors are driving the growth of the opioid use disorder treatment market. The escalating opioid crisis, especially in regions like North America, has significantly increased the demand for effective treatment solutions. Pharmacological treatments such as methadone, buprenorphine, and naltrexone are in high demand due to their effectiveness in managing withdrawal symptoms and cravings. Furthermore, the growing recognition of opioid addiction as a medical condition has encouraged more individuals to seek treatment, further fueling market growth. Increased investments in research and development of innovative treatments, including digital therapeutics, are also contributing to the market’s expansion.
Market Drivers:
Rising Prevalence of Opioid Addiction:
The increasing global prevalence of opioid addiction is one of the main drivers of the Opioid Use Disorder (OUD) Treatment Market. The opioid crisis, particularly in North America, has resulted in a significant rise in addiction and overdose cases, prompting urgent demand for effective treatment options. For instance, the Centers for Disease Control and Prevention (CDC) has reported a notable increase in opioid-related deaths over the last decade. As more individuals seek help for opioid dependence, the demand for specialized treatment programs and medications has grown, directly influencing the market’s growth.
Market Challenges:
Stigma Surrounding Addiction:
A significant challenge in the Opioid Use Disorder (OUD) Treatment Market is the persistent stigma surrounding addiction. Despite increasing awareness of addiction as a medical condition, many individuals still face societal judgment, which discourages them from seeking treatment. This stigma leads to underreporting, delayed diagnosis, and underutilization of available treatment options. Consequently, there is a gap between the actual prevalence of opioid addiction and the number of individuals seeking help, limiting the market's growth potential.
Segmentation:
By Drug Type:
Opioid Agonists: Methadone, Buprenorphine
Opioid Antagonists: Naltrexone
Combination Therapies: Buprenorphine-Naloxone
By Age Group:
Adolescents (12-17 years)
Adults (18-64 years)
Elderly (65+ years)
By Route of Administration:
Oral
Injectable
Transdermal
By Distribution Channel:
Hospitals
Clinics
Retail Pharmacies
By Region:
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Players:
Aphios
MediciNova
Alkermes, Inc.
Titan Pharmaceuticals, Inc.
Trevena
Kyowa Kirin
Gamida-Cell
Hikma Pharmaceuticals
Opiate Pharmaceutical
Novartis AG
Table of Contents
187 Pages
- CHAPTER NO. 1 : INTRODUCTION
- 1.1.1. Report Description
- Purpose of the Report
- USP & Key Offerings
- 1.1.2. Key Benefits for Stakeholders
- 1.1.3. Target Audience
- 1.1.4. Report Scope
- CHAPTER NO. 2 : EXECUTIVE SUMMARY
- 2.1. [Opioid Use Disorder Treatment Market] Snapshot
- 2.1.1. [Opioid Use Disorder Treatment Market], 2018 - 2032 (USD Million)
- CHAPTER NO. 3 : [Opioid Use Disorder Treatment Market] – INDUSTRY ANALYSIS
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Market Opportunities
- 3.5. Porter’s Five Forces Analysis
- CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE
- 4.1. Company Market Share Analysis – 2023
- 4.2. [Opioid Use Disorder Treatment Market] Company Revenue Market Share, 2023
- 4.3. Company Assessment Metrics, 2023
- 4.4. Start-ups /SMEs Assessment Metrics, 2023
- 4.5. Strategic Developments
- 4.6. Key Players Product Matrix
- CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS
- CHAPTER NO. 6 : [Opioid Use Disorder Treatment Market] – BY [By Drug Type] ANALYSIS
- CHAPTER NO. 7 : [Opioid Use Disorder Treatment Market] – BY [By Age Group] ANALYSIS
- CHAPTER NO. 8 : [Opioid Use Disorder Treatment Market] – BY [By Route of Administration] ANALYSIS
- CHAPTER NO. 9 : [Opioid Use Disorder Treatment Market] – BY [By Distribution Channel] ANALYSIS
- CHAPTER NO. 10 : [Opioid Use Disorder Treatment Market] – BY [By Region] ANALYSIS
- CHAPTER NO. 11 : COMPANY PROFILES
- 11.1. Aphios
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio
- 11.1.3. SWOT Analysis
- 11.1.4. Business Strategy
- 11.1.5. Financial Overview
- 11.2. MediciNova
- 11.3. Alkermes, Inc.
- 11.4. Titan Pharmaceuticals, Inc.
- 11.5. Trevena
- 11.6. Kyowa Kirin
- 11.7. Gamida-Cell
- 11.8. Hikma Pharmaceuticals
- 11.9. Opiate Pharmaceutical
- 11.10. Novartis AG
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
